Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Teleflex, Lowers Price Target to $236

Morgan Stanley analyst Drew Ranieri maintains Teleflex (NYSE:TFX) with a Equal-Weight and lowers the price target from $278 to $236.
byBenzinga Newsdesk
October 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Drew Ranieri maintains Teleflex (NYSE:TFX) with a Equal-Weight and lowers the price target from $278 to $236.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Calquence Tablet Formulation Approved in the US Across Current Indications

By Charles Gross
August 5, 7:26 AM
AstraZeneca's new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.

AZN